We are international
Donate
• about myeloma TEXT SIZE   

REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis [programmed cell death] in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells. The compromise of this relationship between the myeloma cell and its microenvironment results in inhibiting production in the BM milieu of cytokines (IL-6, VEGF, TNF-alpha) mediating growth and survival of MM cells and blocking angiogenesis." (from "Myeloma therapy, from the bench to the clinic," Blood; November, 2002 (vol. 100, no.9, p. 3061)

Clinical Trials
Patient Assistance
General Information
REVLIMID®/THALOMID® TIP CARD
This handy tip card includes indications, dosage, and potential side effects.
Understanding Revlimid®
Revlimid® is an immunomodulatory agent. It is a drug that can modify or regulate the functioning of the immune system. These agents appear to have multiple actions, including both anticancer and anti-inflammatory activities.

CITINGS
A quarterly publication featuring the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma. CITINGS provides physicians and other health care professionals with references and Internet links to the most current U.S. and international journal articles, abstracts, and white papers. Several issues have been published on Revlimid™.
Revlimid Prescribing Information, including updated renal dosing guidelines

Celgene Pharmaceuticals
Click here to view their most recent press releases.
From the Archives:
BLOOD Reports Revimid™ Has Anti-Tumor Activity in Patients with Relapsed and Refractory Multiple Mye